CKD273预测慢性肾脏病的研究进展

Research progress of CKD273 in predicting chronic kidney disease

慢性肾脏病(CKD)是全球公共卫生的主要疾病负担之一,目前的检测指标如微量白蛋白尿、肾小球滤过率(GFR)、肾穿刺病理检查等有众多局限性,且不能早期发现及预测疾病发展,因此发现新的能评估健康人群CKD的风险及预测CKD进展的生物标志物非常重要。慢性肾脏病273(CKD273)作为一种新的尿蛋白质生物标志物,不仅能预测微量白蛋白尿水平的变化,还具有预测GFR下降、CKD患者心血管风险及评估临床药物疗效的作用,甚至能监测慢性抗体介导排斥反应。CKD273具有无创性、相对稳定的特点,有望在临床应用中代替目前的诊断标志物。文章就CKD273预测CKD发展、心血管风险、对药物作用等方面的研究进展进行综述。

Chronic kidney disease(CKD)is one of the major disease burdens of global public health.The current detection indicators such as microalbuminuria,glomerular filtration rate(GFR),renal puncture pathological examination,etc.have many limitations,and cannot detect and predict disease development early,so the discovery of new ones can assess the risk of CKD in healthy people and the biomarkers that predict the progression of CKD are very important.Chronic Kidney Disease 273(CKD273),as a new urine protein biomarker,can not only predict changes in microalbuminuria levels,but also predict the decline in GFR,cardiovascular risk in CKD patients,and evaluate the efficacy of clinical drugs.Monitor chronic antibody-mediated rejection.CKD273 is non-invasive and relatively stable,and is expected to replace current diagnostic markers in clinical applications.This article reviews the research progress of CKD273,prediction of CKD development,cardiovascular risk,and drug effects.